2016/10/13 – Quantum Genomics announces 2016 first-half financial results and first nine months business update

2016/09/29 – Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

2016/09/22 – Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension

2016/09/12 – Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

2016/09/06 – Quantum Genomics to Present at Rodman & Renshaw 18th Annual Conference in New York on September 13

2016/06/30 – Quantum Genomics initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

2016/06/28 – Quantum Genomics extends its collaboration agreement with its partner in animal health

2016/05/31 – Quantum Genomics symposium at the European Meeting on Hypertension and Cardiovascular Protection

2016/05/17 – Quantum Genomics granted two new U.S. patents covering lead product QGC001

2016/04/26 – Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure